Bristol-Myers Squibb Co (N:BMY)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: Route 206 And Province Line Road
PRINCETON NJ 08543
Tel: N/A
Website: https://www.bms.com
IR: See website
<
Key People
Giovanni Caforio
Executive Chairman of the Board
Michelle Weese
Executive Vice President - Corporate Affairs, Member of the Leadership Team
Christopher S. Boerner
Chief Executive Officer, Chief Operating Officer, Director
David V. Elkins
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Greg Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Samit Hirawat
Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team
Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Elizabeth A. Mily
Executive Vice President - Strategy and Business Development, Member of the Leadership Team
Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
   
Business Overview
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Financial Overview
For the fiscal year ended 31 December 2023, Bristol-Myers Squibb Co revenues decreased 2% to $45.01B. Net income increased 27% to $8.03B. Revenues reflect Prioritized Brands-Revlimid segment decrease of 39% to $6.1B, Prioritized Brands-Sprycel segment decrease of 11% to $1.93B, United States segment decrease of 1% to $31.56B, other segment decrease of 16% to $699M.
Employees: 34,100 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $135,174M as of Dec 31, 2023
Annual revenue (TTM): $45,006M as of Dec 31, 2023
EBITDA (TTM): $20,625M as of Dec 31, 2023
Net annual income (TTM): $8,025M as of Dec 31, 2023
Free cash flow (TTM): $7,907M as of Dec 31, 2023
Net Debt Last Fiscal Year: $27,492M as of Dec 31, 2023
Shares outstanding: 2,022,193,411 as of Feb 6, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.